Home/Filings/4/0001209191-22-037111
4//SEC Filing

CROSS HERB 4

Accession 0001209191-22-037111

CIK 0001532346other

Filed

Jun 14, 8:00 PM ET

Accepted

Jun 15, 7:14 PM ET

Size

18.0 KB

Accession

0001209191-22-037111

Insider Transaction Report

Form 4
Period: 2022-06-13
CROSS HERB
Chief Financial Officer
Transactions
  • Disposition to Issuer

    Employee stock option (right to buy)

    2022-06-1395,0000 total
    Exercise: $13.97Exp: 2031-01-26Class A Common Stock (95,000 underlying)
  • Award

    Employee stock option (right to buy)

    2022-06-13+95,00095,000 total
    Exercise: $1.84Exp: 2031-01-26Class A Common Stock (95,000 underlying)
  • Award

    Employee stock option (right to buy)

    2022-06-13+224,999224,999 total
    Exercise: $1.84Exp: 2029-04-04Class A Common Stock (224,999 underlying)
  • Disposition to Issuer

    Employee stock o16.74ption (right to buy)

    2022-06-13224,9990 total
    Exercise: $12.06Exp: 2029-04-04Class A Common Stock (224,999 underlying)
  • Award

    Employee stock option (right to buy)

    2022-06-13+97,00097,000 total
    Exercise: $1.84Exp: 2030-02-25Class A Common Stock (97,000 underlying)
  • Disposition to Issuer

    Employee stock option (right to buy)

    2022-06-1397,0000 total
    Exercise: $22.07Exp: 2030-02-25Class A Common Stock (97,000 underlying)
Footnotes (4)
  • [F1]1/48 of the Option vests in equal monthly installments as measured from 1/1/2021. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time.
  • [F2]The transactions reported herein reflect a one-time stock option repricing effective on June 13, 2022 (the "Option Repricing"). The Option Repricing applies to options with exercise prices greater than or equal to $9.00 per share held by all employees of the Issuer as of June 13, 2022. Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.845 per share, the closing price of the Issuer's Class A common stock on the Nasdaq Global Select Market as of the date of the Option Repricing. There have been no other changes to the terms of the repriced options, including the Option. The Option Repricing does not apply to options held by non-employee directors of the Issuer.
  • [F3]1/4 of the Option vests on 2/25/2020 and 1/48 of the Option vests in equal monthly installments as measured from 2/25/2020. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time.
  • [F4]2/48 of the Option vests on 3/1/2020 and 1/48 of the Option vests in equal monthly installments as measured from 3/1/2020. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time.

Issuer

Atreca, Inc.

CIK 0001532346

Entity typeother

Related Parties

1
  • filerCIK 0001230721

Filing Metadata

Form type
4
Filed
Jun 14, 8:00 PM ET
Accepted
Jun 15, 7:14 PM ET
Size
18.0 KB